Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Trial Summary
What is the purpose of this trial?
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.
Research Team
Krin Patel, MD
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Observation
Participants undergo collection of blood samples every 6 months for 3 years. Additional tests such as biopsy, x-rays, PET/CT scans, and MRI scans may be conducted at the discretion of the treating physician.
Follow-up
Participants are monitored every 6-12 months after the initial 3-year observation period to assess progression to multiple myeloma.
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator